FDA approves new test to help determine if breast cancer patients are candidates for Herceptin treatment

Posted by Food and Drug Administration--Press Releases on Tuesday Jun 14, 2011 Under News

The U.S. Food and Drug Administration today approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer treatment.

Be Sociable, Share!

Comments are closed.